Medicinal electronomics bricolage design of hypoxia-targeting antineoplastic drugs and invention of boron tracedrugs as innovative future-architectural drugs.

摘要: We describe herein for the first time our medicinal electronomics bricolage design of hypoxia- targeting antineoplastic drugs and boron tracedrugs as newly emerging drug classes. A new area treatments has recently focused on neoplastic cells tumor environment/microenvironment involving accessory cells. This hypoxic environment is now considered a major factor that influences not only response to therapies but also potential malignant progression metastasis. review drugs, antiangiogenic cell radiosensitizers, sugar-hybrid 10 B delivery agents, in which we candidates based their electronic structures obtained by molecular orbital calculations, solely pharmacophore development. These include an radiosensitizer TX-2036, TX-2244, hypoxia-targeting indoleamine 2,3-dioxygenase (IDO) inhibitors, BNCT agent, BSH (sodium borocaptate- B)-hypoxic cytotoxin tirapazamine (TPZ) hybrid TX-2100. then discuss concept class having broad many areas. Most current cancer target directly. Recently, or therapeutics focuses instead tumor- specific microenvironment (1). The For three decades, have been concentrating much effort development chemical modifiers treatment (2), including cytotoxins, (3), Gc protein-derived macrophage-activating factors (4, 5). provide here thorough strategy tactics bricolage. In particular, progress such elucidation. present vivo developing chick embryo model evaluate radiosensitizing activity compounds against solid neoplasms. syntheses hypoxic-neoplastic functioning 2.3-dioxygenase inhibitors. further show neutron capture therapy (BNCT) agents are promising boron-10 carrier BNCT. Finally, what call 'boron tracedrugs' with next-generation pharmaceutical drugs. Boron designed persistent traceability anytime during lifetime. key structural feature these consists multiple atoms firmly embedded scaffold skeleton located at position will little no influence other functional group moiety pharmacophores.